As the biotechnology sector continues to make strides in delivering next-generation advancements and developments in AI-driven platforms and drug discovery engines, the looming question remains: What trends are impacting emerging biotechnology companies?

Across several interviews with Pharmaceutical Executive, industry experts shared their opinions and insights on recent innovations in drug discovery and industry collaborations, the integration of AI into organizations, and the struggles most companies face from emerging biotechnology startups.

Early-Stage challenges in biotech

Biotech startups operate in a uniquely high-risk environment, as most drug candidates never reach patients. From the start, founders are tasked with balancing scientific ambition with operational execution, all while managing limited capital and regulatory pressures.

Yerem Yeghiazarians, founder and CEO of Soley Therapeutics, in a conversation with Pharmaceutical Executive, emphasized that “drug discovery is difficult. Nobody's saying that it's easy. There's a lot of failures, unfortunately, and it requires time and funding.” For early-stage companies, securing financing, assembling multidisciplinary teams, and executing clinical trials capable of translating preclinical insights into human outcomes are constant challenges.

Common pitfalls of early-stage biotech organizations often stem from overextension or lack of focus.

“You change direction, you rechange direction, you change direction again. That's time, that's effort, that's confusion, and a waste of money,” Yeghiazarians said. He continued to stress the importance of building a strong team with complementary expertise, including researchers, engineers, clinicians, and investors, all while adhering to a clear scientific vision.

“At the early stage, you’ve got to be hands-on, get involved with everything and everyone, and really understand your own limitations,” he added. For emerging biotechs, this combination of strategic focus and operational discipline is critical to navigating high attrition rates and complex regulatory environments.

Integrating AI into biotech operations

As the pharma industry as a whole continues to adopt AI into its everyday operations, AI is rapidly evolving from supplemental tools to the backbone of modern biotech operations.

Darko Matovski, CEO and co-founder of CausaLens, describes AI as moving “from being a simple copilot to becoming the operational baseline of pharma enterprises.” Using autonomous digital workers, multi-agent systems capable of handling complex workflows, companies can automate everything from clinical operations and medical writing to quality assurance and medical information management, all while scaling outputs without adding headcount.

These systems are adaptive, capable of understanding context, and can dynamically adjust to changes in protocol or data, allowing biotech companies to manage the vast, heterogeneous datasets central to drug development.

Regulatory compliance and transparency are also key components to scaling AI adoption. In his conversation with Pharmaceutical Executive, Matovski highlights that “before any output is finalized, independent ‘judge agents’ rigorously evaluate it for accuracy and compliance, ensuring every decision is transparent and explainable, a glass box, not a black box.”

By embedding governance, auditability, and continuous learning, AI can turn compliance from a reactive burden into an integrated workflow advantage. Digital workers operate within regulated systems like Veeva, Oracle, and Argus, automatically validating evidence and reducing rework while maintaining traceability for regulators, investors, and clinicians.

Ethical considerations are increasingly important as AI informs high-stakes decisions, such as patient stratification and treatment personalization. “When AI starts influencing medical decisions, it’s absolutely paramount that we can explain how it works and ensure those outputs are safe and compliant,” Matovski said.

Integrating oversight from the start allows biotech organizations to balance innovation with ethical responsibility. By embedding transparency and real-time auditability, AI not only accelerates operational efficiency but also strengthens trust and reduces regulatory uncertainty, key factors for emerging companies operating under tight timelines and limited capital.

AI also enhances early-stage decision-making, as Loong Wang, CEO and founder of QDX, emphasized in his conversation with Pharm Exec.

Wang noted that computational methods, when combined with AI, enable biotech’s ability to avoid pursuing molecules or programs doomed to fail.

“Good quality computational methods allow you to not bother making/testing chemical matter that is doomed to fail,” Wang explained. Beyond efficiency, AI identifies novel targets, binding pockets, and mechanisms of action that traditional methods might overlook, fundamentally reshaping early-stage strategy and risk management.

Innovations transforming drug discovery

On the discovery front, AI converges with advanced computational methods and quantum chemistry to redefine what is possible in emerging biotech.

Wang notes, “Every drug hunter is going to need to adopt this kind of technology. AI is unavoidable, and quantum chemistry is everywhere: it is quite literally laws of nature.”

These innovations enable modeling of protein-ligand interactions with quantum-mechanical accuracy, simulations of complex chemical reactions, and optimization of synthesis processes—capabilities that were previously impractical or cost-prohibitive.

High-quality computational approaches provide both predictive and explanatory power, as Wang explains, “Black box AI/ML approaches might work for interpolating between your data, but you need approaches that are capable of extrapolation. You also need methods that are able to not only give you a prediction but can give you a physically grounded reason for that prediction.”

In practice, this method allows researchers to understand why a molecule binds effectively, which interactions are critical, and how to optimize chemical design. For early-stage biotechs, these insights are transformative, guiding program prioritization and enabling faster, more efficient progression into preclinical and clinical testing.

Soley Therapeutics embodies the approach, rather than beginning with a disease target, the company identifies molecules that induce desired cellular outcomes, then determines which patient populations and disease contexts are most suitable.

“We discover the molecule at the cell level, do the MedChem to figure out how it works, then figure out which disease and which patients to go after,” Yeghiazarians said.

This cell-first paradigm flips traditional discovery on its head, uncovering novel mechanisms and reducing the risk of failure associated with targeting incorrectly characterized disease pathways.

Broader access to quantum chemistry platforms further expands opportunities for innovation. As Wang explains, QDX’s Exess engine enables biotech companies to model protein systems at scales previously considered impractical, providing detailed insights into molecular interactions, chemical reactions, and enzyme dynamics.

“Until the release of Exess, quantum chemistry has not been practical to use on large systems. These limits are now thrown aside, and we’re excited to see what people do,” Wang said.

By lowering barriers to computational power and enabling more accurate molecular modeling, these technologies enable biotech organizations to tackle previously intractable targets while accelerating discovery across the industry.